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Soluble mite extract (SME)
Poultry red mite
A B S T R A C T
Vaccination is a desirable emerging strategy to combat poultry red mite (PRM), Dermanyssus gallinae. We per-
formed trials, in laying hens in a commercial-style cage facility, to test the vaccine eﬃcacy of a native pre-
paration of soluble mite extract (SME) and of a recombinant antigen cocktail vaccine containing bacterially-
expressed versions of the immunogenic SME proteins Deg-SRP-1, Deg-VIT-1 and Deg-PUF-1. Hens (n = 384 per
group) were injected with either vaccine or adjuvant only (control group) at 12 and 17 weeks of age and then
challenged with PRM 10 days later. PRM counts were monitored and, at the termination of the challenge period
(17 weeks post challenge), average PRM counts in cages containing birds vaccinated with SME were reduced by
78% (p < 0.001), compared with those in the adjuvant-only control group. When the trial was repeated using
the recombinant antigen cocktail vaccine, no statistically signiﬁcant diﬀerences in mean PRM numbers were
observed in cages containing vaccinated or adjuvant-only immunised birds. The roles of antigen-speciﬁc anti-
body levels and duration in providing vaccine-induced and exposure-related protective immunity are discussed.
1. Introduction
One of the biggest challenges facing the global commercial egg in-
dustry is the control of the blooding-feeding poultry red mite (PRM),
Dermanyssus gallinae (De Geer, 1778). The prevalence of PRM in com-
mercial laying facilities is estimated to range from 4 to 100% in several
European countries (Sparagano et al., 2014) but is also high outwith
Europe, for example, 64% in China (Wang et al., 2010) and 85% in
Japan (Sparagano et al., 2014). PRM live mostly oﬀ-host in the struc-
ture and furniture of poultry facilities and emerge in darkness to feed on
the blood of hens for short periods of approximately 30–60 min (Maurer
et al., 1988). A moderate level of infestation in commercial facilities is
considered to be approximately 50,000 mites per bird and this can rise
to 500,000 in severe infestations (Kilpinen et al., 2005). A rise in host
somatic stress indicators (Kowalski and Sokol, 2009) and psychogenic
behaviours such as restlessness, irritation, feather pecking and canni-
balism have been observed in response to PRM infestation (Kilpinen
et al., 2005). In addition, PRM infestation can result in an increase in
anaemia and hen mortality (Wojcik et al., 2000; Cosoroaba, 2001;
Kilpinen et al., 2005; Arkle et al., 2006) and the PRM may also act as
vectors of important avian diseases (Valiente-Moro et al., 2007;
Sommer et al., 2016). Together these eﬀects may result in reduced egg
production, a lower feed conversion and reduced egg quality
(Cosoroaba, 2001; Arkel et al., 2006; Mul et al., 2009). PRM is therefore
a highly economically-important disease and, in 2005, was estimated to
cost the EU egg industry €130 million in production loss and control
costs annually (Van Emous, 2005).
Traditionally the egg industry has relied upon synthetic acaricides
for PRM control (Sparagano et al., 2014). However prolonged use of
these compounds has resulted in the development of acaricide re-
sistance in many countries (Abbas et al., 2014) and legislation has seen
with withdrawal of many compounds, particularly in the EU
(Sparagano et al., 2014). Novel and eﬀective methods of PRM control
are required and vaccination as a control strategy oﬀers several ad-
vantages over existing treatments; vaccines are acceptable to industry,
they are not environmental toxins, resistance is unlikely to develop and
they have the potential to be cost-eﬀective and long lasting (Wright
et al., 2016). Preliminary immunisation studies using diﬀerent crude
fractions of PRM extracts as vaccines have been performed previously
(Arkle et al., 2008; Wright et al., 2009; Harrington et al., 2009; Bartley
et al., 2015; Makert et al., 2016). PRM fed on heparinised blood which
was enriched with IgY from hens vaccinated with PBS-soluble PRM
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proteins (soluble mite extract, SME) had a statistically signiﬁcant
higher rate of mortality than those fed on blood enriched with IgY from
control hens (Wright et al., 2009; Bartley et al., 2015). Following on
from the demonstration of protection using these native extracts, the
challenge has been to simplify these protective PRM protein fractions,
identify the key protein components responsible for protection and
produce eﬀective recombinant versions of the vaccine candidate pro-
teins. The search for vaccine candidates was accelerated when PRM
transcriptomic data became available (Bartley et al., 2009; Bartley
et al., 2012; Schicht et al., 2013, 2014; Makert et al., 2016) and, since
then, a pragmatic approach of combined immuno-screening, proteomic
analysis and MASCOT searching of transcriptomic datasets has been
successful in identifying several such vaccine candidates (Bartley et al.,
2015, Merkert et al., 2016).
To date, the testing of recombinant versions of PRM vaccine can-
didate antigens on PRM survivability following a blood meal from
vaccinated hens has been carried out using an in vitro feeding mite
device based on the McDevitt et al. (2006) design (Bartley et al., 2009,
2012, 2015; Wright et al., 2016). This process was used to identify the
three most eﬀective antigens in vitro: D. gallinae Vitellogenin-1 (Deg-
VIT-1), Serpin-1 (Deg-SRP-1) and a Protein of Unknown Function-1
(Deg-PUF-1) (Bartley et al., 2015).
There are several advantages to the in vitro feeding strategy in
determining vaccine eﬃcacy, for example, antigen-speciﬁc IgY can be
fed to PRMs in a controlled environment and mite mortality, oviposi-
tion and development of individual PRMs can be accurately monitored
with ease. However, the in vitro feeding system lacks natural feeding
cues and feeding rates can be variable (Wright et al., 2009). In addition,
the blood is heparinised which has a residual toxicity (McDevitt et al.,
2006) to PRMs and to induce feeding, the PRMs are pre-starved and
exposed to high temperature, which may elevate background mortality
(Kirkwood, 1971; Bruneau et al., 2001; McDevitt et al., 2006; Wright
et al., 2009; Harrington et al., 2009). Attempts to maintain a laboratory
isolate of PRM ex vivo using in vitro feeding devices have been partially
successful (Bruneau et al., 2001), however PRM survival was severely
diminished following the ﬁrst feed. Therefore, to fully evaluate the ef-
fects of repeated feeding on vaccinated blood and secondary vaccine
eﬀects such as reduced oviposition and impaired development of suc-
cessive generations, a ﬁeld trial that permits natural feeding behaviour
of PRM on live hens, coupled with PRM population monitoring over
many generations is required.
The purpose of the experiments described here was, therefore, to
test the eﬃcacy of the SME and a cocktail vaccine containing re-
combinant versions of the SME-derived proteins Deg-VIT-1, Deg-SRP-1
and Deg-PUF-1 as prototype vaccines under ﬁeld conditions akin to a
commercial layer farm.
2. Materials and methods
2.1. Field trial design
Two ﬁeld trials (trial 1 and trial 2) were performed at the same
poultry facility in East Lothian, Scotland which was free from PRM
before the commencement of each study. Trial 1 ran from 6th July 2010
for 36 weeks and trial 2 from 17th December 2014 for 38 weeks.
In both trials, 768 Lohmann Brown hens were randomly assigned to
one of 2 groups (Placebo and Vaccine groups, 384 hens per group). The
hens were initially group-housed from hatching (=week 0) in a loose
litter ﬂoor pens, with layer mash and water provided ad libitum until
week 17. In keeping with commercial laying hen rearing practices, all
hens received several routine vaccinations and coccidiostat treatments
during the ﬁrst 17 weeks of life. In addition, the Vaccine groups re-
ceived two 0.5 ml doses of prototype PRM vaccine (SME in trial 1; re-
combinant antigen cocktail in trial 2) formulated in adjuvant (Section
2.2), given intra-muscularly into the thigh, at 12 and 17 weeks old. The
Placebo group hens received two 0.5 ml doses of adjuvant in diluent,
also at weeks 12 and 17 and into the thigh. Following vaccination with
the PRM vaccines or placebo, hens were moved to facilities equipped
with a conventional battery cage system (Big Dutchman, Germany)
arranged in a format of 4 lines of 24 cages set in a back to back format
and 4 tiers high (Fig. 1). The top layer of cages remained empty. To
account for the spatial eﬀect due to placement and its proximity of
cages to variable environmental factors, hens were placed 4 per cage
into the alternating group format depicted in Fig. 1.
Neighbouring groups were separated from each other by a single
column of empty cages treated with a double line of adhesive insect
barrier glue (Agralan Ltd., UK), which has since been shown to be ef-
fective in limiting PRM movement (Pritchard et al., 2016). The glue
barriers were applied in continuous lines to the ﬂoor, ceiling, rear and
front of the cages and extended around the feeding trough, egg col-
lection tray, water pipes and ducting to ensure a complete barrier was
in place to reduce PRM migration between adjacent blocks and groups
of cages. Consistent with industry practices, food and water were pro-
vided ad libitum throughout the studies and manure removed daily
using the manure belts located below each tier.
Ten days after the second immunisation and placement of the hens
in the cage system, a PRM challenge infestation was released into the
shed (Section 2.3) and the PRM population was subsequently monitored
(Section 2.4) for the remainder of the challenge period.
Both trials were performed under the terms of UK Home Oﬃce li-
cences (PPL 60/4111 and PPL 60/4324) and the experimental design
was ratiﬁed by the ethics committees of the Moredun Research Institute
and Roslin Nutrition Ltd.
2.2. Preparation of experimental vaccines
2.2.1. Trial 1 vaccines
SME was prepared from 1 g PRM which had been snap-frozen in
Fig. 1. Schematic representation of a cage facility
layout used in the ﬁeld evaluation of prototype
vaccines to control poultry red mite.
Four lines of 24 cages, 4 tiers high were set in a back
to back format. The top tiers of cages are not shown
and were empty. Hens were injected with either the
red mite prototype vaccine (Vaccine group) or ad-
juvant only (Placebo group) and placed 4 hens to a
cage in replicate 8 sub-blocks (SB) comprising of 12
cages of Vaccine and 12 cages of Placebo group hens.
The Vaccinated group were placed in the cages
shaded light grey (trial 1) and dark grey (trial 2) and
the Placebo group in the cages shaded dark grey
(trial 1) and light grey (trial 2). The un-shaded cages
remained empty and served as a buﬀer zone to reduce mite migration between adjacent sub-blocks and groups. Barrier glue (Agralan Ltd., UK) was applied in 2 continuous parallel lines
around each empty cage in the buﬀer zone, around the supporting legs of the housing structure and pipes and ducting.
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liquid nitrogen within 24 h of collection from a commercial layer fa-
cility (Peeblesshire, Scotland) according to the protocol given in Wright
et al. (2009). The SME was ﬁltered through a 0.22 μm cellulose acetate
low-binding ﬁlter unit (Corning Inc., USA) prior to estimating the
concentration of proteins using a Pierce™ bicinchoninic acid (BCA)
assay (Thermo Fisher Scientiﬁc, USA), following the manufacturer’s
protocol. The experimental vaccine was prepared by a commercial
vaccine company (Ridgeway Biologicals Ltd., UK) as follows: SME
proteins were combined, in an emulsion, with the Montanide ISA207VG
water in oil in water adjuvant (SEPPIC, France) in an equal ratio re-
sulting in 285 μg SME present in a single 0.5 ml dose. In trial 1, a
placebo emulsion was also prepared from sterile PBS and Montanide
ISA207VG mixed in the same ratio.
2.2.2. Trial 2 vaccines
Recombinant poly-histidine tagged versions of Deg-SRP-1, Deg-PUF-
1 and the N-terminal portion Deg-VIT-1 encoded by the nucleotide
bases 43–3157, were expressed in Escherichia coli BL21(DE3)-RIPL
competent cells (Agilent Technologies, USA) and aﬃnity-puriﬁed using
His-Trap™ HP columns (GE Healthcare, UK) as described previously
(Bartley et al., 2015). Following puriﬁcation, imdazole was removed
from the soluble Deg-SRP-1 and Deg-PUF-1 proteins by dialysis against
10 mM Tris-HCl; 0.5 M NaCl, pH 7.4 for 16 h at 4 °C. The Deg-VIT-1 was
puriﬁed from the insoluble inclusion bodies. The urea and imidazole
were removed and the Deg-VIT-1 protein refolded by sequential dialysis
against refolding buﬀer (100 mM Tris–HCl, pH 8.0; 0.4 M L-Arginine;
2 mM EDTA; 0.5 mM oxidative glutathione; 5 mM reduced glutathione)
with decreasing concentrations of urea (6, 4, 2 and 1 M urea) and ﬁ-
nally against 10 mM Tris–HCl; 0.5 M NaCl, pH 7.4 for 16 h at 4 °C.
Following ﬁlter sterilisation and protein quantiﬁcation (BCA assay)
equal quantities of the 3 puriﬁed recombinant proteins were combined
and formulated (by Ridgeway Biologicals Ltd., UK) with Montanide
ISA70VG (SEPPIC, France) in a 3:7 ratio of protein to adjuvant. Each
0.5 ml dose contained 25 μg of each recombinant protein. A trial 2
Placebo emulsion was prepared by mixing 10 mM Tris–HCl; 0.5 M
NaCl, pH 7.4 in a 3:7 ratio with Montanide ISA70VG.
2.3. Preparation and release of the poultry red mite challenge into the
poultry house
Mixed developmental-stage and gender PRM were collected into
75 cm2 vented tissue culture ﬂasks (Corning Inc.) at a commercial egg
production unit in Scotland, UK, which had been free from pesticide
treatment for at least 1 month. The mites were collected within a 10 day
period prior to release into the trial shed. The identity of the mites was
conﬁrmed as PRM by PCR-ampliﬁcation of a 737 bp fragment of the
Cytochrome C oxidase -1 subunit (COX-1), DNA sequencing and phy-
logenetic analysis following the method of Oines and Brannstrom
(2011). The challenge isolate partitioned with the ‘haplotype A group’,
closely related to PRM isolates previously characterised from Finland
and Scotland (results not shown).
PRMs were maintained at room temperature (RT) for 1–5 days and
192 individual doses (each containing ∼20,000 PRMs in trial 1;
∼10,000 PRMs in trial 2) of PRMs were prepared in universal tubes
(Sterilin) ﬁtted with a vented lid (Corning Inc.). The prepared live PRM
challenge doses were then maintained at 7 °C at 75% humidity for a
maximum of 4 days until required. Each universal tube of PRM was
attached to the egg collection rack located at the front of each stocked
cage and out of reach of the hens. The PRMs were released from the
universal tube by piercing the ﬁlter in the vented cap several times. The
universal tube was left in place until the end of the study to serve as a
refuge for PRMs. At the same time as the infestation was initiated, a
mite monitoring device (Elanco, USA) (see Section 2.4) was attached to
the egg collection rack adjacent to the mite challenge tube to also serve
a refuge for the emerging mites. The refuge traps remained in place for
the duration of the trials.
2.4. Monitoring poultry red mite populations
PRM populations were monitored in both trials using ADAS-type
MiteMonitor trap devices (Elanco). Mite trap counting was performed
at 7 time points in trial 1 (at weeks 20.5, 22.5, 27, 29.5, 32, 34 and 36
post hen hatching) and 9 time points in trial 2 (weeks 21, 23, 25, 27, 29,
31, 33, 35 and 37 post hen hatching). Trap holders were attached to the
egg collection tray, adjacent to the refuge trap. The corrugated plastic
trap insert were placed into each holder for 24 h, then removed and
immediately placed into 50 ml Sterilin falcon tubes (Thermo Fisher
Scientiﬁc, USA) containing 10 ml 70% (v/v) ethanol to kill the PRMs.
The dead PRMs were ﬂushed from the corrugated traps using 70% (v/v)
ethanol, transferred to a Petri dish and then manually counted with the
aid of a dissecting microscope. In addition to counting the total num-
bers of mites per trap, the population composition was estimated in trial
2 by counting the numbers of adults and juveniles PRMs present in a
subset of 32 traps (2 from each replicate block). The proportions of the
adult and juvenile populations were expressed as a percentage of the
total number of mites per trap
2.5. Evaluation of the immune response to vaccination and challenge
The generation and persistence of IgY responses were quantiﬁed by
ELISA and Western blotting. In trial 1, 8 eggs were collected from each
group (1 egg from each replicate sub-block) at weeks 20, 27, 29 and 36
and equal volumes of yolk from each egg were pooled according to
group and time. In trial 2 serum IgY levels were measured at weeks 12
(pre-vaccination), 17, 19 and thereafter at weeks 23, 27, 31, 35 and 38.
Yolk-IgY levels were also measured from eggs collected at these time
points from week 19 onwards. Blood was withdrawn by venesection of
the brachial wing vein of 1 bird randomly selected from each replicate
sub-block group. Serum was recovered following clotting at 4 °C for
24 h and centrifugation at 3000 × g and stored at−20 °C. In trial 2 the
serum and yolk samples were evaluated individually to allow the var-
iation in individual hen responses to be assessed.
For ELISA, the wells of Microlon® high-binding 96-well microplates
(Greiner Bio-one, UK) were coated overnight at 4 °C with 50 μl of an-
tigen (SME, integral membrane mite extract (IMME, prepared as de-
scribed in Wright et al., 2009) or each of the recombinant antigens)
diluted at 10 μg/ml in coating buﬀer (50 mM sodium bicarbonate, pH
9.6). Plates were washed six times with 200 μl PBST (PBS containing
0.05% v/v Tween-20) to remove unbound antigen and non-speciﬁc
binding was blocked with 200 μl/well of blocking buﬀer (10% w/v
Infasoy (Cow&Gate, UK) in tris-buﬀered saline/Tween 20 (TBST)
buﬀer (50 mM Tris, 150 mM NaCl, 0.05% v/v Tween20)) for 2 h at RT
with agitation. Following washing with PBST buﬀer, 50 μl of sera or egg
yolks diluted to an appropriate concentration (1/4000 for detection of
recombinant antigens and 1/400 for native protein extracts) in TBST
were placed into appropriate wells and incubated at RT for 1 h with
agitation. Plates were washed as before and the bound IgY detected by
incubation for 1 h with agitation at RT with 50 μl/well of rabbit anti-
IgY-peroxidase conjugate (Sigma, UK), diluted 1/30,000 in TBST. Fol-
lowing washing as before, bound secondary antibody was detected with
50 μl/well of the colorimetric substrate o-Phenylenediamine dihy-
drochloride (SIGMAFAST™ OPD, Sigma, UK). The colorimetric reaction
was stopped after 20 mins by the addition of 25 μl of 2.5 mM H2SO4 to
each well and the A490nm of each well measured using an ELX808IU
Ultra Microplate Reader (Bio-Tek Instruments, UK).
For Western blotting, 4 μg of SME prepared from engorged mites or
100 ng of recombinant antigen per lane were separated by electro-
phoresis on 12% Bis–Tris Novex gels in NuPAGE® MES SDS Running
Buﬀer (GE Healthcare, UK). Proteins were transferred to nitrocellulose
membrane using an Xcell II blot module (GE Healthcare, UK), following
the manufacturer’s procedures. Western blot screening and develop-
ment were carried out as previously described (Bartley et al., 2009).
Brieﬂy, individual lanes of the membrane were excised and blocked by
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incubation in 5% (w/v) Marvel skimmed milk in PBST at 4 °C for 12 h,
washed in PBST, then probed with yolk or serum diluted 1/250 in PBS
for 2 h at RT. Unbound IgY was washed oﬀ with PBST. Bound IgY was
detected by incubation in rabbit anti-IgY-peroxidase conjugate (Sigma,
UK), diluted 1/30,000 in PBS for 1 h at RT, followed by washing in
PBST and colorimetric development with SIGMAFAST™ 3,3′-Diamino-
benzidine substrate (Sigma,UK).
2.6. Statistical analyses
For the purpose of statistical analyses of the PRM count data and to
account for spatial eﬀects due to placement and proximity of cages to
variable environmental factors, the house was partitioned into four
blocks (Blocks 1-4) with each block comprising of two sub-blocks (SB 1-
8). For each trial separately, a Poisson generalized additive mixed
model (GAMM) with a logarithmic link function was ﬁtted by penalised
maximum-likelihood (PQL) estimation to test for diﬀerences in mean
PRM counts between Vaccinated and Placebo groups over time. The
model included the treatment group as ﬁxed eﬀect and spline-based
smooth terms (one per treatment group) to account for the non-linear
relationship of the response variable with time. The eﬀect of sub-block
within block was regarded as a random eﬀect. A dispersion parameter
was estimated to take into account excessive variability in the data.
Trial 1 showed a delayed increase in PRM numbers and generated
negligible number of counts in the ﬁrst two time points. Therefore only
data from week 27 on were considered in trial 1 for GAMM ﬁtting.
Diﬀerences in mean PRM trap counts at the end of the experiment
(week 36 for trial 1 and week 38 from trial 2) were statistically tested
by ﬁtting a Poisson generalized linear mixed model (GLMM). In trial 2
the same model was ﬁtted to also test for diﬀerences at the point of
peak response (week 33), and the corresponding p-values were adjusted
for multiplicity by controlling for false discovery rate (FDR). The
Poisson GLMMs included group as ﬁxed eﬀect and a random intercept
for each sub-block within block. An observation-level random eﬀect
was speciﬁed to account for over-dispersion. Diﬀerences in mean pro-
portion of juvenile PRMs between Vaccinated and Placebo groups
measured over 4 weeks in trial 2 (based on 16 mite traps from each
group) were statistically tested by ﬁtting a binomial GLMM. Statistical
signiﬁcance was assessed at the 5% signiﬁcance level. All statistical
analyses were carried out using R software version 3.2.4 (R Core Team,
2016).
3. Results
3.1. The poultry red mite populations
The mean numbers of PRM per trap for the Vaccine and Placebo
groups over the course of both trial 1 (SME vaccine trial) and trial 2
(recombinant antigen cocktail vaccine trial) are shown in Fig. 2. In-
dividual trap data for both trials are available in Supplementary Data
File 1.
In trial 1, the increase in PRM numbers in both Placebo and Vaccine
groups was initially slow, characterised by a 10.5 week lag period in
population expansion following challenge. After week 29, an expansion
in PRM populations was observed in both groups (Fig. 2A). The PRM
trap numbers peaked in the Vaccine group at week 34 and then de-
clined, whereas PRM numbers in the Placebo group continued to rise
until the end of the study. The diﬀerence between mean PRM counts in
the Vaccine and Placebo groups over time, were analysed using a
GAMM. Statistically signiﬁcant diﬀerences in mean PRM counts were
observed between the Vaccine and Placebo groups (p < 0.001), over
the time period extending from 27 to 36 weeks. Analysis of group dif-
ferences at the challenge endpoint individual time points was per-
formed using GLMM. Statistically signiﬁcant diﬀerences were observed
between the mean PRM counts of the Vaccine and Placebo groups at the
challenge endpoint (week 36) of the trial (p < 0.001), with mean PRM
numbers in the Vaccine group (366.24 ± 27.44) being 78% less than
those in the Placebo group (1671.34 ± 123.60).
In contrast to the slow PRM population growth following challenge
in trial 1, a shorter lag period of 4.5 weeks was observed in trial 2
(Fig. 2B). After week 23, a rapid expansion in PRM populations was
observed in both Vaccine and Placebo groups in trial 2. Numbers
peaked in both groups at week 33 and the mean peak PRM counts
numbers were not statistically signiﬁcantly diﬀerent (p= 0.058) be-
tween the Vaccine group (736.56 ± 46.03) and the Placebo group
(623.55 ± 39.70). After the week 33 peak, PRM numbers declined in
both groups following a similar pattern. No statistically signiﬁcant
diﬀerences in mean PRM counts over the course of trial 2 were observed
between the Vaccine and Placebo groups (p= 0.338). Furthermore, at
the end of the trial (week 37), there was no statistically signiﬁcant
diﬀerence (p= 0.232) between the mean trap counts for the Vaccine
(243.45 ± 16.70) and Placebo (215.84 ± 12.42) groups.
To investigate any eﬀects of the recombinant vaccine on PRM po-
pulation structure in trial 2, the numbers of juvenile and adult PRMs
were counted in 16 mite traps from each group at 4 trap points (weeks
25, 29, 33 and 37). The mean proportions of juvenile PRMs (overall
mean of the 4 trapping points in Vaccine group was equal to
74.23 ± 5.51% and 72.15 ± 5.60% in the Placebo group) were not
statistically signiﬁcantly diﬀerent whether the traps came from Placebo
or Vaccine group hens (p= 0.397).
Fig. 2. The changes in poultry red mite populations over time during ﬁeld evaluation of
prototype poultry red mite vaccines.
Hens in trial 1 (panel A) were immunised with a prototype vaccine containing a soluble
mite protein extract (Vaccine group) or adjuvant only (Placebo group). Hens in trial 2
(panel B), received a recombinant antigen cocktail vaccine containing Deg-SRP-1, Deg-
VIT-1 and Deg-PUF-1 (Vaccine group) or adjuvant only (Placebo group). Live mites were
released into the cage system at week 18.5. Approximately every 2 weeks thereafter, a
mite trap was placed into each cage (n = 96 per group) for a 24 h period and the mites in
each trap were manually counted with the aid of a dissecting microscope. The mean
number of mites per trap is plotted for both the Vaccine groups (solid black line) and
Placebo groups (broken black line) for each time point. The error bars represent the
standard error of the mean (S.E.M.).
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3.2. IgY levels in response to immunisation and to challenge with PRM
In trial 1, pools of yolks randomly sampled from 8 hens from each of
the Vaccine and Placebo groups at weeks 20, 27, 29 and 36, were tested
for IgY speciﬁc for the SME (Fig. 3). A high ELISA O.D. value (A490nm
range 0.76–0.98) of the Vaccine group yolk pool was observed fol-
lowing vaccination and challenge and was maintained throughout the
trial. In contrast, the Placebo group yolk pool ELISA A490nm remained
consistently low (range 0.17–0.35) throughout the trial. The A490nm in
both groups followed a similar trend: as PRM numbers increased, so did
the A490nm. A similar trend in A490nm was observed in the IMME antigen
ELISAs (Supplementary Fig. S1).
In trial 2, the longevity and magnitude of individual hen’s responses
to each of the recombinant antigens were evaluated using serum IgY
ELISAs. The individual hen and the mean Vaccine and Placebo group
responses to Deg-SRP-1, Deg-PUF-1 and Deg-VIT-1 antigens at 8 time
points are presented in Fig. 4 along with the PRM population data for
comparison. Most hens in the Vaccine group produced high levels of
antigen-speciﬁc IgY to Deg-SRP-1, Deg-VIT-1 and Deg-PUF-1 following
primary immunisation and secondary boosting at 12 and 17 weeks old
respectively. Maximum antigen-speciﬁc IgY levels were reached at
weeks 17, 19 and 23 for Deg-PUF-1, VIT-1 and SRP-1 respectively; after
which the antigen-speciﬁc IgY levels diminished rapidly. Peak IgY le-
vels to Deg-PUF-1 and Deg-VIT-1 occurred before the PRM population
started to expand (week 23) and the IgY levels to Deg-SRP-1 peaked at
week 23. In contrast, the Placebo group hens maintained a low vaccine
antigen-speciﬁc IgY level against all 3 recombinant vaccine antigens
throughout the course of trial 2.
Yolk-IgY ELISAs were performed in parallel with serum-IgY ELISA
(Supplementary Fig. S2) and largely reﬂected the patterns observed for
the serum IgY ELISAs.
3.3. Hen IgY levels against native antigens following poultry red mite
exposure
In order to investigate the generation of an IgY response to PRM
infestation over the course of trial 2, the IgY responses against extracts
of PRM antigens (SME and IMME) were monitored in Vaccine and
Placebo group hens using serum-IgY ELISAs (Fig. 4) and yolk-IgY
ELISAs (Supplementary Fig. S2, panels D and E).
The generation of a PRM-speciﬁc serum-IgY during infestation was
observed in both Vaccinated and Placebo hens and was directed to-
wards antigens present in both SME and IMME. Substantial increases in
the levels of serum- and yolk-SME and IMME-speciﬁc IgY were ob-
served in both Vaccine and Placebo groups from week 25 onwards. The
rise in PRM antigen-speciﬁc serum IgY levels was comparable in both
treatment groups, and was therefore not related to PRM-vaccination
status of the hen. The rise in PRM antigen-speciﬁc serum IgY levels in
both groups coincided with the onset of the rapid increase in PRM
populations. Following a reduction in PRM numbers towards the end of
the trial, the mean PRM antigen speciﬁc serum IgY levels of the Vaccine
and Placebo groups against the SME and IMME antigens became static
or reduced. A peak in native PRM antigen-speciﬁc serum and yolk IgY
levels at week 19 following vaccine boosting was observed in the
Vaccine group, but not the Placebo group (Fig. 4, Supplementary Fig.
S2), suggesting that one of more of the recombinant vaccine antigens
was represented in native form in the SME and IMME preparations.
3.4. The immuno-reactive proﬁles of hens in response to vaccination and
poultry red mite infestation
In trial 1, the yolk-IgY from the Vaccine group, collected 3 weeks
after secondary immunisation, reacted strongly with multiple protein
bands present in the SME (Fig. 5, panel A), indicating a vigorous and
multi-antigen response to immunisation with SME. Reactivity was
predominately seen in the mid (35 kDa) to the high (> 188 kDa) mol.
wt range. In contrast, only 2 bands were obvious in the immunoblots
probed with Placebo group yolk IgY at the same time point. These 2
bands were also detected in the anti-IgY-HRP control lane (Fig. 5, panel
C) and are IgY fragments derived from the ingested blood meal present
in the digestive tract of the PRMs used in the preparation of SME. Band
intensity in the immunoblots probed with yolk IgY from Vaccine group
hens decreased at mid points in the trial (weeks 27 and 29), which
coincided with low PRM numbers and the lower A490nmobtained at
these time points with the yolk-IgY SME ELISA (Fig. 3). Thereafter,
increased band intensity and complexity were observed at week 36 that
diﬀers in proﬁle to that detected with Placebo group yolk-IgY from the
same time point.
In trial 2, the only immuno-reactive bands detected in immunoblots
of SME probed with serum from the Vaccine and Placebo groups at
week 12 (pre-immunisation) corresponded to the IgY fragments derived
from the ingested host blood meal contained in the PRM extract (Fig. 5,
panel B). Following immunisation of hens with the 3 recombinant an-
tigens, additional immuno-reactive bands on immunoblots of both SME
(Fig. 5, panel B) and puriﬁed recombinant proteins (Fig. 5, panel C)
probed with serum from the Vaccine group hens were visible at weeks
17, indicating a speciﬁc antibody response to vaccination with the re-
combinant PRM antigens and also the ability of IgY raised against the
recombinant proteins to bind native versions of some of these proteins
in SME. Thus, high mol. wt bands (> 188 kDa) corresponding to the full
length native Deg-VIT-1 (210 kDa) and some lower mol. wt bands that
may correspond to native forms of processed Deg-VIT-1 were detected
Fig. 3. The yolk IgY levels during ﬁeld trial evaluation of a prototype poultry red mite vaccine containing soluble mite protein extract (SME).
The IgY levels in pooled yolk sampled from hens immunised with SME (Vaccine group, panel A), or adjuvant only (Placebo group, panel B), at weeks 20, 27, 29 and 36 of trial 1, were
quantiﬁed using an ELISA with SME as coating antigen. The anti-SME IgY levels (represented by A490nm) in the pooled yolk samples are plotted (solid black line) and the PRM populations
data from the Vaccine and Placebo groups are overlaid (broken black lines), with the error bars giving the S.E.M.
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Fig. 4. The generation and longevity of serum IgY levels speciﬁc for the individual components of a prototype poultry red mite recombinant antigen cocktail vaccine and native protein
preparations during ﬁeld trial evaluation.
The speciﬁc IgY levels of individual hens from the Vaccine (left panels) and Placebo (right panels) groups in trial 2 to the individual recombinant vaccine antigens: Deg-SRP-1, Deg-PUF-1,
Deg-VIT-1 and the native protein mite extracts: soluble mite extract (SME) and integral membrane mite extract (IMME) were quantiﬁed using ELISAs. The antigen-speciﬁc IgY levels
(represented by A490nm) of 8 individual hens randomly sampled from each group at 9 time points, are indicated with black diamonds (♦) and the mean response with the solid black line.
The timings of the primary and secondary vaccinations (V1 and V2) and of the mite challenge (Ch) are indicated with the arrows on x-axis. The mite population data of Vaccine and
Placebo groups are overlaid (broken black lines), with the error bars giving the S.E.M.
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in immunoblots of SME probed with sera from Vaccine group hens by
weeks 17 and 19 (Fig. 5, panel B). Bands corresponding with the pre-
dicted mol wt. of native forms of Deg-SRP-1 (42 kDa) and Deg-PUF-1
(20 kDa) were not clearly visible in immunoblots of SME probed with
sera from Vaccine group hens (Fig. 5, panel B) suggesting that these
proteins are of low abundance in SME and below the detectable level by
Western blotting.
Following challenge, as the PRM populations increased in both the
Vaccine and Placebo groups in trial 2, a diverse immuno-reactive pro-
ﬁle emerged in immunoblots of SME probed with sera from both
Vaccine and Placebo group hens over time. The proﬁles for the Vaccine
and Placebo groups at week 38 were similar to each other, with notable
diﬀerences in the band intensities in a high mol. wt. band (> 188 kDa)
and a lower mol. wt band at approximately 38 kDa. In addition, the
proﬁles that emerged in both groups of hens at weeks 35 and 38 in trial
2, were comparable to those seen in the trial 1 Vaccine group (see bands
marked with a line on Fig. 5 panels A and B).
4. Discussion
Here we have demonstrated, for the ﬁrst time, the eﬃcacy of a
prototype PRM vaccine containing native proteins in a soluble mite
extract (SME) in a commercial-style laying hen facility. The SME-based
vaccine reduced PRM population size by up to 78% (trial 1). Previous
studies demonstrated the feasibility of using vaccination with similar
native PRM protein extracts to generate speciﬁc IgY immunoglobulins
that induce PRM mortality when ingested in a blood meal (Wright et al.,
2009; Harrington et al., 2009; Bartley et al., 2015). However, these
studies were performed on a small scale, in a laboratory environment
and the measurable vaccine eﬀects were limited to mite mortality after
a single heparinised blood meal delivered in vitro using an artiﬁcial
mite feeding apparatus. In contrast, the reduction in PRM population
numbers attributable to vaccination in the ﬁeld-type trial described
here incorporates several vaccine eﬀects, such as mortality, morbidity
and fecundity.
Previous immuno-proteomic analysis of SME identiﬁed several
promising individual vaccine candidate antigens which induced
statistically-signiﬁcant increases in PRM mortality when blood from
hens immunised with recombinant forms of each of the antigens was
fed to PRM on a small-scale using the in vitro artiﬁcial feeding device
(Bartley et al., 2015). In this current study (in trial 2), we selected three
of the most promising of these vaccine candidates, Deg-SRP-1, Deg-
PUF-1 and Deg-VIT-1, and performed the ﬁrst large-scale PRM vaccine
ﬁeld trial using recombinant vaccine candidates. In spite of their eﬃ-
cacy individually in the in vitro feeding trials, the combined re-
combinant cocktail vaccine did not confer protective immunity in im-
munised hens in the ﬁeld trial. The reasons for the inability of the
recombinant cocktail vaccine to control PRM numbers in the ﬁeld trial
may include inappropriate antigen selection, and/or an inadequate
protective response in terms of magnitude and longevity.
As all 3 recombinant antigens performed strongly in previous in
vitro mite feeding assays (Bartley et al., 2015) and the antigen choice
was based on their apparent potential. PRMs fed in vitro on blood from
hens immunised with each of these antigens individually were more
than twice as likely to die than those fed on blood from control hens
(Bartley et al., 2015). Combining recombinant antigens into a cocktail
vaccine has also been a useful method to enhance vaccine eﬃcacy
against parasites (cf. Nisbet et al., 2013; Burgess et al., 2016). In ad-
dition, Deg-VIT-1 is structurally similar to a second high performing
antigen from the in vitro feeding screen, hemelipoglycoprotein (Deg-
HGP-1), which induced signiﬁcant PRM mortality in the previous stu-
dies (Bartley et al., 2015). These two proteins share many functional
domains and were shown, by Western blotting, to be immunological
cross-reactive (Bartley et al., unpublished data). Therefore vaccination
with one protein may have the additional beneﬁt of conferring cross-
protection immunological cross-reactivity against the other. Likewise,
Deg-SRP-1 also had a rational basis for its inclusion into the re-
combinant antigen cocktail vaccine: in addition to the induced mor-
tality in PRM feeding on sera from hens immunised with recombinant
Deg-SRP-1 (Bartley et al., 2015), previous vaccination studies on sev-
eral tick species have shown that serpin-based vaccines induce a variety
of eﬀects including: increased parasite mortality, reduced reproductive
parameters and interference with feeding (Sugino et al., 2003; Imamura
et al., 2005, 2006; Prevot et al., 2007; Jittapalapong et al., 2010; Kim
Fig. 5. The changes in immuno-reactivity over time during the ﬁeld trial evaluation of prototype poultry red mite vaccines.
Individual lanes of a western blot of soluble mite extract (SME) protein were probed with pooled egg yolks from hens from trial 1 assessing a SME prototype vaccine (panel A) or with
pooled serum from trial 2 testing a recombinant antigen cocktail prototype vaccine (panel B). Pooled yolk or serum from Vaccinated hens (VAC) and the Placebo hens (PLAC) obtained at
several time points throughout the trials were tested (trial 1: weeks 20, 27, 29 and 36; trial 2: weeks 12,17,19,23,27,31,35 and 38). Bound IgY was detected with rabbit anti-IgY-
peroxidase conjugated antibody (Sigma, UK). PBS was substituted for the primary IgY and served as a conjugate control (conj, panel B). Additional controls were performed for trial 2
(panel C): individual western blot strips of the puriﬁed recombinant antigens: Deg-Serpin-1 (SRP), Deg-protein of unknown function-1 (PUF) and Deg-Vitellogenin (VIT) were probed with
trial 2 serum pool from the Placebo group (−) and Vaccine group (+) obtained following vaccination (week 17). The bands marked with asterisk (*) indicate the detection of host IgY
fragments present in SME. Bands marked with the lines (−) indicate immuno-reactive bands common to both in trial 1 and 2 Vaccine groups that developed following prolonged
infestation with poultry red mite. The approximate mol. wt (kDa) of detected proteins were estimated by comparison to SeeBlue® Plus2 pre-stained standards (GE Healthcare, UK).
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et al., 2016). In contrast, the ﬁnal protein included into the re-
combinant antigen cocktail, Deg-PUF-1, has no ascribed putative
function. However, as Deg-PUF-1 produced the highest rates of mor-
tality seen in the 10 antigens tested using the in vitro feeding studies
(Bartley et al., 2015), it was selected for inclusion in the recombinant
antigen cocktail vaccine.
Following immunisation with the recombinant protein cocktail,
wide variation was observed in the magnitude of the initial antigen-
speciﬁc IgY levels of individual hens to the vaccine components (Fig. 4).
The mean recombinant antigen-speciﬁc IgY levels peaked at between
17 to 23 weeks, and then rapidly diminished before any substantial rise
in PRM numbers occurred. It is therefore likely that the poor longevity
of the vaccine-induced antibody response is largely responsible for the
inability of the vaccine to control the rise in PRM numbers. In addition,
the recombinant-antigen speciﬁc IgY levels were not boosted by ex-
posure to high numbers of feeding PRMs. Therefore the choice of ad-
juvant is likely to be crucial for vaccination with these recombinant
antigens to produce a sustained, protective response. The adjuvant used
in trial 2, Montanide™ ISA70VG, synthetic oil in water in oil prepara-
tion, was chosen for its demonstrated safety and eﬃcacy in other
poultry vaccines (e.g. Dupuis et al., 2006; Jawale and Lee, 2016) but,
on this occasion, sustained recombinant antigen-speciﬁc IgY levels were
not observed. There was also little evidence for a substantial ana-
mnestic response to recombinant antigens in the Vaccine group hens
following PRM exposure. This suggests that either the antigens need to
be administered in a suitable adjuvant as described above or that vac-
cine boosting would need to be performed during the lay period for
sustained protection. Repeated PRM vaccination using an injection
route is unlikely to be acceptable to industry, given the practical and
economic implications of mass vaccination of commercial ﬂocks, which
often exceed 50,000 hens. To overcome the challenges of mass vacci-
nation, many of the current commercial poultry vaccines are adminis-
tered in drinking water or by aerosol spraying during the rearing period
(e.g. vaccines which protect against Salmonella: SALMUNE® (CEVA,
France) and Gallivac Se (Merial, France); Infectious Bronchitis and
variants: CEVAC® IBird (CEVA), Infectious Bursal Disease: CEVA-
C®GUMBO L (CEVA) and Gallivac IBD (Merial); Newcastle Disease:
CEVAC® VITAPEST L (CEVA)) and these may be coupled with an initial
injectable vaccine either to prime an initial response or to boost re-
sponses just before the lay period (Knott et al., 2008). Alternative oral
delivery routes for avian vaccine antigens include delivery in food (e.g.
Zhou et al., 2004; Jacob et al., 2013; Ito et al., 2013; Kolotilin et al.,
2014) and a similar regime may be beneﬁcial in maintaining a strong
response to a PRM vaccine if the delivery method was to result in an-
tigen-speciﬁc circulating serum antibodies.
An alternative method to produce a sustained protective immune
response would be to select a novel set of vaccine antigens from those
proteins which generate a powerful immune response during natural
parasite exposure. By their nature these “exposed antigens” should
generate vaccine-induced antibody levels following immunisation
which would be further boosted during natural infestation (Willadsen
and Kemp, 1988; Munn, 1993; Nuttall et al., 2006). We have shown
here, for the ﬁrst time, that serum IgY levels against exposed PRM
antigens increase with the duration and level of PRM infestation and
that, after these IgY levels reach a peak, PRM numbers started to reduce
(Fig. 4). This is in contrast to results obtained by Arkle et al. (2006),
where a low PRM-speciﬁc serum IgY level was measured throughout
the lay period of commercial hens and no signiﬁcant relationship be-
tween antibody level and PRM numbers was observed. However, the
antigen used in the ELISA in the Arkle et al. (2006) study was prepared
from membrane extracts from starved PRMs which would probably lack
many exposed antigens and many of the PRM proteins that are upre-
gulated and secreted/excreted by feeding mites.
The shift in the speciﬁcity of the IgY response in hens vaccinated
with SME (trial 1), from a diﬀuse response against a multitude of SME
antigens at the start of infestation, to a focused response against fewer
antigens later in the trial, coupled with reduction in PRM numbers,
lends support for using a targeted approach using exposed antigens. It is
clear from the problems caused by huge numbers of PRM in laying
sheds (Van Emous, 2005) that the hens’ immune response to natural
infestations is “too little, too late” to prevent PRM population expansion
but, if the hens were already primed with a vaccine containing these
exposed antigens (as in trial 1, here) the PRM populations may be
controlled. Very little is currently known about the underlying me-
chanism(s) of adaptive protective immune response in hens to PRM but
it may prove to be as complex as in other blood-feeding ectoparasite
species. For example, in Rhipicephalus microplus infestation, immune-
mediated resistance is associated with several factors including high
levels of speciﬁc immunoglobulins, strong T-helper-1 (Th1) type re-
sponse, particularly hypersensitivity with associated eosinophil and
mast cell degranulation and increases in gamma-delta T-cells and
CD25+ cells (reviewed Jonsson et al., 2014). Studies examining cyto-
kine and chemokine gene expression levels and patterns in hens during
the ﬁrst 5 and 22 days of exposure to PRM did not identify any statis-
tically signiﬁcant diﬀerences in expression of selected Th1 and T-
helper-2 (Th2) molecules (Harrington et al., 2010a; 2010b). There was
however, a possible trend towards a Th1 response in the ﬁrst 24 h post-
infestation, followed by down regulation of Th1 responses at 48 h post
infestation (Harrington et al., 2010a). After the removal of the PRMs on
day 5, increases in IFNγ and IL-6 were observed; leading to the sug-
gestion that PRM-mediated immuno-modulation of the host response
may also be important for successful PRM feeding. Despite the lack of a
clearly deﬁned Th1/Th2 paradigm response, statistically signiﬁcant
increases in IgM and IgY levels, speciﬁc for PRM protein extracts, were
observed over 22 days of infestation (Harrington et al., 2010b). This
increase in IgY and IgM levels occurred concurrently with a decrease in
the PRM oviposition rates, indicating a potential immunoglobulin
mediated eﬀect on PRM fecundity. As supplementation of blood meals
with puriﬁed anti-PRM-IgYs induced mortality in feeding PRMs (Wright
et al., 2009) and there is a statistically signiﬁcant relationship between
IgY level and mortality in this system (Harrington et al., 2009); it is
clear that vaccine-induced humoral responses, at least, are implicated
in vaccine eﬃcacy. Similarly, the generation of a strong serum antibody
response against the blood-feeding avian ectoparasite mite Ornitho-
nyssus sylviarum during heavy infestations (DeVaney and Ziprin, 1980)
is associated with a reduction in parasite burden (DeVaney and
Augustine, 1988; Wikel et al., 1989). However, factors other than host
antibody response are also important in natural acquired immunity to
O. sylviarum, such as MHC-inﬂuenced skin inﬂammatory responses
which are able to restrict the ability of the mite to reach the host ca-
pillaries and obtain a blood meal (Owen et al., 2008, 2009). Similar
histopathological changes (e.g. epidermal hyperplasia, hyperkeratosis
and parakeratosis) are also characteristic of PRM infestation of hens
(Sokól and Rotkiewicz, 2010; Hobbenaghi et al., 2012), although the
implications of the skin changes in the resistance of hens to PRM are
unknown.
The dynamics of PRM population growth were diﬀerent in trial 1
and 2, with growth in PRM populations being much slower in trial 1
Vaccine and Placebo groups, possibly as a consequence of seasonality
and a lower external temperature. The development of PRM exposed
antigen-speciﬁc IgY in vaccinated hens in trial 1 developed after just 5
weeks of rapidly rising PRM numbers (between weeks 29 to 34),
whereas in trial 2 a similar response, in terms of both antigen proﬁle
and immunoreactivity, was observed after a longer period of 11 weeks
of rapid PRM population growth. This suggests that the IgY response to
exposed antigens during infestation develops more quickly in SME-
immunised birds in response to increasing PRM numbers, possibly as a
consequence of prior exposure to these antigens in the SME vaccine.
In conclusion, we have demonstrated that vaccine-induced im-
munity is able to reduce PRM population numbers in commercial style
laying facilities. In addition, prolonged exposure to high numbers of
PRMs may result in some degree of mite control through the
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development of natural acquired immunity. The vaccination trial using
a recombinant vaccine cocktail has demonstrated the diﬃculties in
maintaining a sustained IgY level throughout the laying period. The
challenge is now to engineer a recombinant antigen-based vaccine
capable of producing a response of suﬃcient magnitude and longevity
that does not rely upon high numbers of PRM to continually boost the
protective response. It is likely that such a vaccine would have an im-
proved protective capacity during the early phase of the lay cycle, when
PRM numbers are low and thus prevent PRM numbers reaching a level
where they impact on the health, welfare and production of laying
hens.
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